Tag: Childbirth
Neighborhood Disadvantage Tied to Higher Postpartum Depression Risk
Findings seen across Black, White, and Asian individuals but not Hispanic individuals
New Postpartum Depression Drug Comes With Hefty Price Tag
Zurzuvae not only presents a new way to treat postpartum depression, but it also 'appears to be fast-acting'
Postpartum Medicaid Extensions Address Some Health, Social Needs
Medicaid respondents reported less use of primary, specialty, and dental care in the postpartum year
Childbirth Tied to Medical Debt, Even Among Commercially Insured Families
Risk for medical debt in collections highest for postpartum individuals living in lowest-income neighborhoods
Delivery at 39 Weeks May Be Best for Pregnancies Conceived Via Infertility Treatment
39 weeks provides the lowest perinatal risk versus risk at the subsequent week of gestation
Publication of ARRIVE Trial Linked to Increase in 39-Week Induction
Increase in 39-week induction rate, reduction in rate of cesarean delivery observed after publication of trial in August 2018
FDA Gives Approval to Pill to Ease Postpartum Depression
Zurzuvae works faster than conventional antidepressants and is easier to take than another postpartum depression drug that is delivered intravenously
Oxycodone Does Not Increase Risk for Persistent Opioid Use After Delivery
No significant association seen overall or after cesarean delivery, but association was significant for vaginal delivery
Zuranolone Beneficial for Treatment of Postpartum Depression
Significant improvement seen in 17-item Hamilton Depression Rating Scale, Clinical Global Impressions severity score
Maternal Labor Epidural Analgesia May Be Linked to Autism in Children
Risk increased with labor epidural analgesia alone and labor epidural analgesia and oxytocin compared with no exposure
